Status:
COMPLETED
Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis
Lead Sponsor:
Pfizer
Conditions:
Arthritis, Rheumatoid
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine the long-term effectiveness and safety of CP-690,550 for the treatment of rheumatoid arthritis. Subjects are eligible for this study only after participating ...
Eligibility Criteria
Inclusion
- Subjects who have participated in a randomized "qualifying" study of CP-690,550 for the treatment of rheumatoid arthritis
- Vaccine sub-study visit
- Subjects actively participating in Study A3921024 must have completed at least 3 months of continuous 10 mg BID CP-690,550 treatment in A3921024 as defined by \>80% compliance with prescribed dose consumption of CP-690,550 over the previous 3 months.
Exclusion
- Serious medical conditions that would make treatment with CP-690,550 potentially unsafe
- Vaccine sub-study visit
- Any documented influenza or pneumococcal infection within the last 3 months prior to randomization in this study
- Received any vaccine within 1 month prior to randomization in this study
- Received an influenza vaccine within 6 months or a pneumococcal vaccine within 5 years of randomization in this study.
Key Trial Info
Start Date :
February 5 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 26 2017
Estimated Enrollment :
4488 Patients enrolled
Trial Details
Trial ID
NCT00413699
Start Date
February 5 2007
End Date
October 26 2017
Last Update
October 30 2018
Active Locations (469)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
2
Rheumatology Associates of North Alabama, PC
Huntsville, Alabama, United States, 35801
3
Arthrocare, Arthritis Care & Research, PC
Gilbert, Arizona, United States, 85234
4
Arizona Arthritis & Rheumatology Associates, P.C.
Phoenix, Arizona, United States, 85032